| scholarly article | Q13442814 |
| P50 | author | Paola Secchiero | Q39507349 |
| Giorgio Zauli | Q39507392 | ||
| Bruno Fabris | Q42413436 | ||
| Silvano Capitani | Q56493863 | ||
| Assunta Pandolfi | Q57318080 | ||
| Riccardo Candido | Q114516463 | ||
| Federica Corallini | Q114516464 | ||
| Claudio Celeghini | Q114717345 | ||
| P2093 | author name string | Agostino Consoli | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand | Q24653311 | ||
| TRANCE is a TNF family member that regulates dendritic cell and osteoclast function | Q28137948 | ||
| Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression | Q28192264 | ||
| Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin | Q28295204 | ||
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis | Q28589430 | ||
| Endothelial function: a critical determinant in atherosclerosis? | Q35789874 | ||
| Endothelial inflammation in insulin resistance | Q36039598 | ||
| Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death | Q43510191 | ||
| TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells | Q43821708 | ||
| Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells | Q44022379 | ||
| Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications | Q44490286 | ||
| Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand | Q44534331 | ||
| RANKL regulates endothelial cell survival through the phosphatidylinositol 3′‐kinase/Akt signal transduction pathway | Q44590687 | ||
| Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis | Q44801373 | ||
| A stable prostacyclin analogue reduces high serum TNF-alpha levels in diabetic patients | Q44967655 | ||
| Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction | Q45149635 | ||
| Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. | Q45256838 | ||
| Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women | Q46130374 | ||
| Association of osteoprotegerin with human abdominal aortic aneurysm progression | Q46531394 | ||
| Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. | Q46670294 | ||
| Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients | Q46871108 | ||
| Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status | Q57927784 | ||
| TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release | Q59225302 | ||
| Increased osteoprotegerin serum levels in men with coronary artery disease | Q73106368 | ||
| Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men | Q73167301 | ||
| Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis | Q73684776 | ||
| PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways | Q74308465 | ||
| Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease | Q74711101 | ||
| Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis | Q80413873 | ||
| Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors | Q81550347 | ||
| The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects | Q83304478 | ||
| Decreased endomyocardial RANKL expression in transplant coronary artery disease | Q83864020 | ||
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| P304 | page(s) | 2236-2244 | |
| P577 | publication date | 2006-12-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction | |
| P478 | volume | 169 |
| Q45941637 | A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. |
| Q93055493 | Association of Glycated Proteins with Inflammatory Proteins and Periodontal Disease Parameters |
| Q39197051 | Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus |
| Q37285702 | Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact |
| Q40041063 | Dyslipidemia and Diabetes Increase the OPG/TRAIL Ratio in the Cardiovascular System |
| Q89982455 | Early endothelial activation precedes glycocalyx degradation and microvascular dysfunction in experimentally induced Plasmodium falciparum and Plasmodium vivax infection |
| Q34304606 | Effect of 635 nm irradiation on high glucose-boosted inflammatory responses in LPS-induced MC3T3-E1 cells |
| Q51277910 | Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes. |
| Q44498958 | Effect of topical application of melatonin to the gingiva on salivary osteoprotegerin, RANKL and melatonin levels in patients with diabetes and periodontal disease. |
| Q50950745 | Exercise-induced vasodilation in healthy males: A marker of reduced endothelial function. |
| Q59224640 | Hydrogen sulfide down-regulates the expression and release of osteoprotegerin (OPG) by vascular endothelial cells |
| Q38946503 | Hydroxyoctadecadienoic acids regulate apoptosis in human THP-1 cells in a PPARγ-dependent manner. |
| Q55381832 | Intravascular haemolysis in severe Plasmodium knowlesi malaria: association with endothelial activation, microvascular dysfunction, and acute kidney injury. |
| Q64116561 | Inverse regulation of serum osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand levels in patients with leg lesional vascular calcification: An observational study |
| Q35127451 | Long Term Effect of High Glucose and Phosphate Levels on the OPG/RANK/RANKL/TRAIL System in the Progression of Vascular Calcification in rat Aortic Smooth Muscle Cells |
| Q42930757 | Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy |
| Q37597984 | Medial arterial calcification in diabetes and its relationship to neuropathy. |
| Q64884087 | Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin. |
| Q61217312 | Obesity and Glucose Metabolism |
| Q33891378 | Osteoporosis, fractures, and diabetes |
| Q60668215 | Osteoprotegerin and biomarkers of vascular inflammation in type 2 diabetes |
| Q35926521 | Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes |
| Q35640787 | Osteoprotegerin in Cardiometabolic Disorders |
| Q38889912 | Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events |
| Q34229800 | Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes |
| Q37310825 | Osteoprotegerin, vascular calcification and atherosclerosis |
| Q42443622 | Parathyroid hormone decreases endothelial osteoprotegerin secretion: role of protein kinase A and C. |
| Q44230417 | Pegylated TRAIL retains anti-leukemic cytotoxicity and exhibits improved signal transduction activity with respect to TRAIL. |
| Q64882601 | Plasma Osteoprotegerin Correlates with Stroke Severity and the Occurrence of Microembolic Signals in Patients with Acute Ischemic Stroke. |
| Q45865145 | Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: a multicenter and multiethnic study. |
| Q64944581 | RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain. |
| Q46844245 | Reduced attenuation of bone resorption after oral glucose in type 2 diabetes |
| Q37782447 | Relation between serum osteoprotegerin and carotid intima media thickness in a general population – the Tromsø Study |
| Q42181735 | SNP rs2073618 of the osteoprotegerin gene is associated with diabetic retinopathy in Slovenian patients with type 2 diabetes |
| Q37641079 | Serum Osteoprotegerin Is a Potential Biomarker of Insulin Resistance in Chinese Postmenopausal Women with Prediabetes and Type 2 Diabetes |
| Q41317574 | Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. |
| Q46084662 | Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males? |
| Q55052506 | TNF-alpha modulates the migratory response of mesenchymal stem cells to TRAIL. |
| Q41123139 | TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications |
| Q63915339 | TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe −/− mice |
| Q64266102 | TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets? |
| Q40912538 | The Effects of Initial Periodontal Therapy on the Serum Receptor Activator of Nuclear Factor-κβ Ligand/Osteoprotegerin System in Patients With Type 2 Diabetes Mellitus and Periodontitis |
| Q55285084 | The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox |
| Q27012497 | The alliance of mesenchymal stem cells, bone, and diabetes |
| Q38056541 | The role of osteoprotegerin in cardiovascular disease |
| Q42489788 | Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells |
| Q33803504 | Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes |
| Q89396602 | Type 2 diabetes is associated with higher trabecular bone density but lower cortical bone density: the Vietnam Osteoporosis Study |
| Q38754124 | Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. |
Search more.